Literature DB >> 32873778

Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms.

Matteo Giaccherini1,2, Angelica Macauda1,2, Nicola Sgherza3,4, Juan Sainz5,6,7,8, Federica Gemignani1, Josè Manuel Sanchez Maldonado5,6,7, Manuel Jurado5,6,7, Francesca Tavano9, Grzegorz Mazur10, Andrés Jerez11, Joanna Góra-Tybor12, Aleksandra Gołos13, Francisca Hernández Mohedo6,7, Joaquin Martinez Lopez14, Judit Várkonyi15, Raffaele Spadano3, Aleksandra Butrym16, Federico Canzian17, Daniele Campa1.   

Abstract

Telomere length measured in leukocyte (LTL) has been found to be associated with the risk of developing several cancer types, including myeloproliferative neoplasms (MPNs). LTL is genetically determined by, at least, 11 SNPs previously shown to influence LTL. Their combination in a score has been used as a genetic instrument to measure LTL and evaluate the causative association between LTL and the risk of several cancer types. We tested, for the first time, the "teloscore" in 480 MPN patients and 909 healthy controls in a European multi-center case-control study. We found an increased risk to develop MPNs with longer genetically determined telomeres (OR = 1.82, 95% CI 1.24-2.68, P = 2.21 × 10-3, comparing the highest with the lowest quintile of the teloscore distribution). Analyzing the SNPs individually we confirm the association between TERT-rs2736100-C allele and increased risk of developing MPNs and we report a novel association of the OBFC1-rs9420907-C variant with higher MPN risk (ORallelic = 1.43; 95% CI 1.15-1.77; P = 1.35 × 10-3). Consistently with the results obtained with the teloscore, both risk alleles are also associated with longer LTL. In conclusion, our results suggest that genetically determined longer telomeres could be a risk marker for MPN development.

Entities:  

Mesh:

Year:  2020        PMID: 32873778      PMCID: PMC7463014          DOI: 10.1038/s41408-020-00356-5

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN: 2044-5385            Impact factor:   11.037


Introduction

Myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem-cell disorders, characterized by increased production of differentiated cells of the myeloid lineage[1-3]. The main types of MPNs are chronic myeloid leukemia (CML), characterized by the presence of the Philadelphia chromosome, and the JAK2/CALR/MPL mutation-related MPNs group, also called Philadelphia chromosome negative, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)[4]. The pooled worldwide crude rate incidence of MPNs is 2.58/100,000 per year[5]. MPNs are an elderly disease with a large increase in risk after the age of 60, and are more common in men than in women[3]. Several epidemiologic factors, such as body mass index (BMI), smoking behavior, alcohol consumption, benzene exposure, and physical activity have been associated with one or more specific subgroups of MPNs[1]. Moreover, there are several evidences for a causative role of somatic mutations in MPN development, such as the V617F mutation in the JAK2 gene and mutations in CALR and MPL[6,7]. In addition, common low penetrance variants have been associated with the disease risk, in particular, seven single nucleotide polymorphisms (SNPs) have been identified through three genome-wide association studies (GWAS)[6,8,9] and, through case–control studies, additional hits such as the 46/1 JAK2 haplotype[10] and several SNPs belonging to genes involved in DNA repair, apoptosis, inflammation, and detoxification[11-16]. In addition, telomere length measured in leukocyte (LTL) has also been investigated as a marker of susceptibility for MPN. LTL is a good proxy for telomere length in other tissues and is relatively stable even across long periods of time[17,18]. LTL has been associated with risk of developing several neoplasms[18-25]. Five studies have investigated the possible correlation between LTL and MPN risk and all have found a correlation between short telomeres and increased risk of development of the disease[26-31]. Even though the findings seem conclusive, all these studies may suffer from common pitfalls that have to be considered when analysing LTL in relation to neoplastic diseases. All the studies were retrospective and therefore could be influenced by reverse causation bias (i.e., the disease and/or therapies causing the decrease in LTL) as described in a review on LTL association studies[32]. In addition, molecular technologies such as FISH or qPCR are prone to measurement errors due to heterogeneity of biological sample collection, storage, and manipulation[33]. Finally, the studies had a small average sample size (130 cases and 155 controls) that could lead to an overinterpretation of the results. Telomere length is, at least partially, genetically determined, and 11 SNPs have been identified, through GWAS, to affect LTL[23,34,35]. To overcome the biases of using the direct measure of LTL, the genetic score combination of these 11 SNPs has been successfully used as proxy of genetically determined LTL to investigate its association with various cancer types[23,36-43]. Noteworthy, the associations between LTL and cancer risk have not consistently shown the same trend if the LTL was measured directly through qPCR or through the genetic score[22,23,36,44]. With these premises, we have tested the “teloscore” in 480 MPN cases and 909 controls in a European multi-center case-control study.

Materials and methods

Study population

Biological samples were collected in four European countries (Hungary, Italy, Poland, and Spain) and included 480 cases and 909 controls. MPN cases were diagnosed according to the WHO 2008 criteria, and 149 CML, 173 ET, 36 PMF, and 122 PV have been collected. Controls were selected at the same centers where cases were collected and were frequency matched to the cases for age and sex. More in detail: in Spain, Poland and Italy all controls were healthy blood donors arising from the general population that declared to be free of neoplastic pathologies at the moment of the interview. In Hungary, they were recruited at the internal medicine department and were patients diagnosed with any diseases other than malignancies or immunopathological disorders (like arteriosclerosis, liver cirrhosis, myocardial events, stroke, metabolic diseases, nephroliths or colitis). The characteristics of the study population are summarized in Table 1. At diagnosis, all the information about the patients was collected from medical records, namely age, sex, country of origin, and V617F JAK2 mutation status. Following the guidelines of the Declaration of Helsinki, written informed consent was obtained from each participant. The study was approved by local Institutional Review Boards, namely by the Bioethics Commission of the University of Medical Sciences, Wroclaw, Poland (KB-746/2017); the Bioethical Commission at the Institute of Hematology and Transfusiology, Warsaw, Poland (17/2018); the Regional and Institutional Committee of Science and Research Ethics of Semmelweis University, Budapest, Hungary (263–1/2015); Comitato Etico presso la Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy (MPN-V1.0_20 Nov 17); Comité de Etica de la Investigaciòn, Servicio Andaluz de Salud, Granada, Spain (4092018), by Comité de Ética de la Investigación con Medicamentos del Hospital Universitario 12 de Octubre, Madrid, Spain (18/092); Comité de Ética de la Investigación con Medicamentos del Hospital General Universitario José María Morales Meseguer, Murcia, Spain (EST: 03/19).
Table 1

Summary of study population.

MPN casesControls
Country
 Hungary4375
 Italy45182
 Poland212132
 Spain180520
Total480909
Sex
 Male43.54%49.72%
 Female56.46%50.28%
Median age (25th–75th percentile)56.46 (45.0–68.5)52.68 (46.0–60.0)
Disease subtype
 CML149
 ET173
 MF36
 PV122
Summary of study population.

SNP selection

We selected 11 SNPs (ZNF676-rs412658, TERT-rs2736100, CTC1-rs3027234, DHX35-rs6028466, PXK-rs6772228, NAF1-rs7675998, ZNF208-rs8105767, OBFC1-rs9420907, ACYP2-rs11125529, TERC-rs10936599 and ZBTB46-rs755017) to be used for the teloscore computation. Each SNP has been discovered by a GWAS and is associated with LTL[23,34,35,45]. Characteristics of the selected SNPs are summarized in Table 2.
Table 2

SNPs associated with telomere length.

SNPGeneChrPositionEAOAEAFβ (SE)Base pairsaDiscovery PvalueDiscovery study
rs412658ZNF6761922,359,440TC0.350.086 (0.010)103.21.00 × 10−8Mangino[34]
rs8105767ZNF2081922,032,639GA0.280.064 (0.011)76.81.11 × 10−9Codd[35]
rs3027234CTC1178,232,774CT0.780.103 (0.012)123.62.00 × 10−8Mangino[34]
rs9420907OBFC110103,916,707CA0.130.142 (0.014)170.47.00 × 10−11Levy[45]
rs755017ZBTB462062,421,622GA0.120.019 (0.013)22.86.71 × 10−9Codd[35]
rs6028466DHX352039,500,359AG0.070.058 (0.013)69.62.57 × 10−8Haycock[23]
rs7675998NAF14163,086,668GA0.760.048 (0.012)57.64.35 × 10−16Codd[35]
rs10936599TERC3169,774,313CT0.760.100 (0.011)1203.00 × 10−31Codd[35]
rs11125529ACYP2254,248,729AC0.110.065 (0.012)788.00 × 10−10Codd[35]
rs6772228PXK358,390,292TA0.960.041 (0.014)49.23.91 × 10−10Haycock[23]
rs2736100TERT51,286,401CA0.50.085 (0.013)1024.38 × 10−19Codd[35]

EA effect allele, OA other allele, EAF effect allele frequency in the Caucasian population, β (SE) estimate of telomere length variation for each copy of EA.

aBase pairs: estimate in base pairs of telomere length variation for each copy of EA, as described in Codd[35].

SNPs associated with telomere length. EA effect allele, OA other allele, EAF effect allele frequency in the Caucasian population, β (SE) estimate of telomere length variation for each copy of EA. aBase pairs: estimate in base pairs of telomere length variation for each copy of EA, as described in Codd[35].

Sample preparation and genotyping

DNA was extracted from whole blood using QIAampR 96 DNA QIAcubeR HT Kit (Qiagen, Hilden, Germany). Genotyping was performed in 384-well plates, using the TaqMan technology (ThermoFisher Applied Biosystems, Waltham MA, USA) according to the manufacturer’s instructions. Each plate contained cases and controls, duplicated samples (8%) were used to check the quality of the genotyping, and negative controls were also added to each plate. Information about the case/control status of the samples was not available to the person performing the genotyping. PCR plates were read on a ViiA 7 Real-Time PCR System and genotypes were called with the QuantStudio software (ThermoFisher Applied Biosystems, Waltham MA, USA).

Teloscore computation

The “teloscore” was built weighing the effect of each SNP on LTL, based on the knowledge of the allele associated with LTL increase. The estimate of the per-allele effect on LTL for each SNP (expressed in base pairs) was taken from the literature[23]. The score was computed as follows: to each subject and for each genotype a value equal to 0, 1 or 2 was assigned, based on the number of alleles associated with longer telomeres. Then for each SNP in each subject, we multiplied the number of alleles associated with longer telomeres and the per-allele effect on LTL in base pairs. Finally, we summed up the estimated effect of each genotype for each study subject, obtaining a score for each subject. Only a subset of study subjects had a 100% genotyping call rate (330 cases and 687 controls). Therefore, a scaled teloscore was computed with all the subjects included in the study, by dividing the score by the number of genotypes available for each subject. We have not tested the teloscore in our data (i.e., the association between the SNPs and TL measured with RT-PCR), however, the estimate of the effect of each allele has been computed using thousands of individuals in the original studies and we consider it reliable. We will use the wording “genetically determined” telomere length to identify the telomere length predicted by the score throughout the manuscript. Supplementary Table 1 shows an example of how the teloscore was computed.

Statistical analysis

The association between each SNP and MPN risk was tested with unconditional logistic regression, computing odds ratios (ORs) and 95% confidence intervals (CI), adjusting for age, sex and country of origin. The analysis was performed with allelic (log-additive) and co-dominant models of inheritance, and, considering the Bonferroni correction for multiple testing, the threshold of statistical significance was P = 0.05/(11 SNPs × 2 models) = 0.05/22 = 0.0023. For the teloscore analysis, cases were distributed in quintiles based on the distribution of values in controls. The analyses were performed with unconditional logistic regression computing ORs and 95% CIs, adjusting for age, sex, and country of origin.

Bioinformatic tools

Each SNP with statistically significant results in the risk association analysis was examined with bio-informatic tools to evaluate a plausible biologic mechanism to explain the association. First, RegulomeDB (https://www.regulomedb.org/regulome-search/)[46] was used to identify the regulatory potential of each SNP analyzed and the SNPs in LD with them. Then, SNPs with the most interesting regulatory potential were analyzed with the Genotype-Tissue Expression (GTEx) portal web site (https://www.gtexportal.org) to identify potential associations between the SNPs and gene expression (i.e., if the SNPs were expression quantitative trait loci, eQTL)[47].

Results

All the selected SNPs were in Hardy-Weinberg equilibrium in the control population. From a total of 503 cases and 929 controls, we excluded 23 cases and 20 controls with a genotyping call rate lower than 72.7% (i.e. we kept samples with at least 8 called SNPs out of 11), leaving 480 cases and 909 controls to use in the statistical analysis with an average genotyping call rate of 97.0%. The concordance rate with duplicated samples was higher than 99%.

Association of the “teloscore” with MPN risk

We tested the association between the weighted teloscore and MPN risk, using the average scores computed for all the individuals. The observed trend was an increased risk of MPN with longer genetically determined telomere length, comparing individuals in the highest quintile with those in the lowest quintile (OR = 1.82; 95% CI 1.24–2.68; P = 2.21 × 10−3) (Table 3).
Table 3

association between weighted teloscore and MPN risk.

Type of scoreQuintilesOR95% CIpvalue
Weighted, subjects with 100% call rate11Ref.
21.040.65–1.680.857
31.40.88–2.230.153
41.380.87–2.170.171
51.751.12–2.740.014
Continuousa1.151.04–1.276.00 × 10−3
Weighted scaled, all subjects11Ref.
21.250.84–1.870.271
31.651.11–2.450.012
41.541.04–2.270.031
51.821.24–2.682.21 × 10−3
Continuousa1.151.05–1.251.55 × 10−3

The p-value are bold statistically significant.

aThe unit for the analysis with the continuous variable was the increment of one quintile.

association between weighted teloscore and MPN risk. The p-value are bold statistically significant. aThe unit for the analysis with the continuous variable was the increment of one quintile. The same trend was observed in the teloscore analyses in the subset of samples with 100% genotyping call rate (330 cases and 687 controls), comparing individuals in the highest quintile with those in the lowest quintile (OR = 1.75; 95% CI 1.12–2.74; P = 0.014) (Table 3). TERT-rs2736100 is well-known in the literature to be associated with MPN risk[48] and it might have pleiotropic effects. We replicated the teloscore analysis without this polymorphism, using the other 10 SNPs to test if the association discovered was driven by the presence of TERT-rs2736100. The result observed was in agreement with the result obtained with 11 SNPs (Supplementary Table 2).

Association between individual SNPs and MPN risk

We observed a statically significant association (considering the Bonferroni-corrected threshold) between TERT-rs2736100-C and increased risk of developing MPNs (ORHeterozygous = 1.69; 95% CI 1.27–2.22; P = 2.89 × 10−4) and a suggestive association between OBFC1-rs9420907-C and increased risk of MPNs (ORAllelic = 1.43; 95% CI 1.15–1.77; P = 1.34 × 10−3). The results of the analysis are shown in Table 4.
Table 4

association between single SNPs and MM risk.

SNPGeneAlleleMAFAllelic modelaCodominant modelb
M/mOR95% CIPValueORHet95% CIPValueORHom95% CIPValue
rs412658ZNF676C/T0.351.070.89–1.280.4971.160.88–1.510.2901.070.71–1.590.746
rs8105767ZNF208A/G0.281.090.90–1.320.3800.970.74–1.250.7971.410.90–2.200.136
rs3027234CTC1C/T0.221.010.83–1.240.9061.180.91–1.520.2070.690.38–1.240.220
rs9420907OBFC1A/C0.131.431.15–1.771.35 × 10−31.320.99–1.750.0532.421.33–4.383.62 × 10−3
rs755017ZBTB46A/G0.120.860.64–1.140.2910.770.55–1.060.1031.730.54–5.570.356
rs6028466DHX35G/A0.071.120.81–1.530.4951.180.83–1.670.3660.810.19–3.480.776
rs7675998NAF1G/A0.241.050.86–1.280.6451.040.81–1.330.7871.130.66–1.950.653
rs10936599TERCC/T0.241.10.89–1.350.3801.140.88–1.470.3161.080.61–1.940.786
rs11125529ACYP2C/A0.110.890.67–1.160.3740.940.70–1.260.6930.450.13–1.560.209
rs6772228PXKT/A0.041.640.97–2.700.0631.560.92–2.630.099
rs2736100TERTA/C0.51.331.12–1.591.49 × 10−31.691.27–2.222.89 × 10−41.671.18–2.384.21 × 10−3

Results in bold are statistically significant.

MAF minor allele frequency, OR odds ratio, 95% CI 95% coefficient interval.

aAllelic model: M vs m, common allele vs rare allele.

bCodominant model: Mm vs MM, heterozygous vs common homozygous; mm vs MM, rare homozygous vs common homozygous.

cDominant model: mm vs Mm + MM, rare homozygous vs heterozygous + common homozygous.

dRecessive model: mm + Mm vs MM, rare homozygous + heterozygous vs common homozygous.

association between single SNPs and MM risk. Results in bold are statistically significant. MAF minor allele frequency, OR odds ratio, 95% CI 95% coefficient interval. aAllelic model: M vs m, common allele vs rare allele. bCodominant model: Mm vs MM, heterozygous vs common homozygous; mm vs MM, rare homozygous vs common homozygous. cDominant model: mm vs Mm + MM, rare homozygous vs heterozygous + common homozygous. dRecessive model: mm + Mm vs MM, rare homozygous + heterozygous vs common homozygous.

Stratified analyses

Stratified analysis according to JAK2 mutation status was also performed for the teloscore and for each individual SNP. The results of the teloscore were in agreement with the analysis done regardless of JAK2 status, with genetically determined longer LTL associated with increased risk of developing MPNs, although the association reached statistical significance only in the JAK2+ stratum (Supplementary Table 3). The analysis of the individual SNPs showed two additional borderline associations for ZNF208-rs8105767 (p = 0.027) and for ZBTB46-rs755017 (p = 0.037) in the JAK2+ stratum and no additional hits (Supplementary Table 4).

Possible functional effect

We tested with bioinformatic tools the possible functional effect of the individual SNPs associated with risk of MPNs, and we found that RegulomeDB assigns to OBFC1-rs9420907 a rank of 3a that indicates that the region where the SNP lies is probably a transcription factor binding site in a DNase sensible region.

Discussion

Telomeres are structures with a continuous decrease of length in each cell replication, due to the inability to replicate the ends of the chromosome[49]. LTL has been extensively investigated in relation to cancer risk, with several studies suggesting an association between short LTL, as well as long LTL with increased risk and some studies suggesting a null association or a bimodal association[18-25,50]. Five relatively small retrospective studies have been attempted to identify the relationship between the LTL and MPNs risk through FISH or qPCR. We used a different strategy and computed a genetic score as proxy for LTL and observed that genetically determined longer telomeres were significantly associated with an increased risk of developing MPNs. These results are in contrast with what was observed before i.e. increased risk of MPNs and short LTL. The discrepancies in the findings could be explained by the fact that the direct measure of LTL is plagued by several possible biases. For example, retrospective studies are often influenced by reverse causation bias, especially if chemotherapy is not taken in consideration when estimating the association. In addition, exposure to several risk factors, such as smoking and BMI, is associated with short LTL and tends to confound the association if not accounted for properly. Finally, the decrease of TL is highly correlated with the increase of age, and the measurement of LTL could be affected by bias due to the different age at blood drawing of the cases and controls included in the studies[32,33]. On the contrary, the genetic risk score has the advantage of being independent from study design and from the environmental factors known to be associated with a variation of LTL. The use of genetic proxies to understand the causative correlation between environmental risk factors and outcome has become more and more popular in the last years and it has been instrumental in identifying several of such associations[23,36-43]. The sample size of our study is almost four times larger than the average size of the previous studies (480 vs 130) if considering only the cases and almost five times larger if considering cases and controls combined (1389 vs 285). We have also analyzed the effect of each SNP and we replicated the well-known association between the TERT-rs2736100-C allele with an increased risk of developing MPNs[6,51-53]. The TERT-rs2736100-C allele has been consistently associated with longer LTL[21,35], possibly through the regulation of the telomerase activity[48]. Another potentially interesting association was observed between the OBFC1-rs9420907-C allele and increased risk of MPN. The gene product of OBFC1 is a member of the CST complex, that is involved in telomere maintenance, and it is a member of the alpha accessory factor (AAF), that is involved in the initiation process of DNA replication[54]. It is interesting to note that also the OBFC1-rs9420907-C allele is associated with long LTL[45]. Regulome DB assigns to the SNP a rank of 3a indicating a mild possibility of this SNP to be involved in the regulation of nearby genes, however, without in vitro studies, it is not possible, with this level of evidence, to draw a definitive conclusion on the variant. The association of these two SNPs is consistent with what we observed for the score, i.e. the alleles associated with increased MPN risk are also associated with longer LTL. Moreover, an additional SNP PXK-rs6772228-T showed the same trend observed for TERT-rs2736100-C and OBFC1-rs9420904-C, with the T allele, known to be associated with longer LTL, correlated with a non-statistically significant increase of risk of developing MPNs. A possible limitation of this study is that the controls we selected did not undergo screening to detect myeloid-specific clonal mutations and therefore they might present clonal hematopoiesis, which is a known precursor of hematopoietic malignancies[8,55,56], however, even if some controls do have clonal hematopoiesis, this could only dilute the true associations between the exposure and the outcome, and not create spurious ones. Telomere length measured through teloscore could be a possible marker of cells that have the innate tendency to have higher dividing potential. Longer TL may facilitate the acquisition and accumulation of new harmful potential mutations that could increase the risk of developing cancer disease[23]. Taken together, all these evidences point towards an association between longer LTL and increased risk of developing MPNs despite what has been reported previously. example of teloscore computation association between weighted teloscore without TERT-re2736100 and MPN risk teloscore analysis stratified by JAK2 status individual SNP analyses stratified by JAK2 status
  56 in total

1.  Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms.

Authors:  Emmanouil Spanoudakis; Ioanna Bazdiara; Despoina Pantelidou; Ioannis Kotsianidis; Vasilios Papadopoulos; Dimitrios Margaritis; George Xanthopoulidis; Eleftherios Moustakidis; Stamatia Mantzourani; George Bourikas; Costas Tsatalas
Journal:  Leuk Res       Date:  2010-09-09       Impact factor: 3.156

2.  Dysregulation of shelterin factors coupled with telomere shortening in Philadelphia chromosome negative myeloproliferative neoplasms.

Authors:  Jenny Dahlström; Xiaolu Zhang; Mehran Ghaderi; Malin Hultcrantz; Magnus Björkholm; Dawei Xu
Journal:  Haematologica       Date:  2015-07-16       Impact factor: 9.941

Review 3.  Surrogate tissue telomere length and cancer risk: shorter or longer?

Authors:  Lifang Hou; Xiao Zhang; Andrew J Gawron; Jie Liu
Journal:  Cancer Lett       Date:  2012-01-21       Impact factor: 8.679

4.  Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C>T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms.

Authors:  Adrian P Trifa; Claudia Bănescu; Delia Dima; Anca S Bojan; Mihaela Tevet; Valeriu G Moldovan; Ștefan C Vesa; Meilin Murat; Ioan V Pop; Cristina Skrypnyk; Radu A Popp
Journal:  Hematology       Date:  2016-03-30       Impact factor: 2.269

5.  The association of telomere length and cancer: a meta-analysis.

Authors:  Ingrid M Wentzensen; Lisa Mirabello; Ruth M Pfeiffer; Sharon A Savage
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-05       Impact factor: 4.254

6.  Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study.

Authors:  Philip C Haycock; Stephen Burgess; Aayah Nounu; Jie Zheng; George N Okoli; Jack Bowden; Kaitlin Hazel Wade; Nicholas J Timpson; David M Evans; Peter Willeit; Abraham Aviv; Tom R Gaunt; Gibran Hemani; Massimo Mangino; Hayley Patricia Ellis; Kathreena M Kurian; Karen A Pooley; Rosalind A Eeles; Jeffrey E Lee; Shenying Fang; Wei V Chen; Matthew H Law; Lisa M Bowdler; Mark M Iles; Qiong Yang; Bradford B Worrall; Hugh Stephen Markus; Rayjean J Hung; Chris I Amos; Amanda B Spurdle; Deborah J Thompson; Tracy A O'Mara; Brian Wolpin; Laufey Amundadottir; Rachael Stolzenberg-Solomon; Antonia Trichopoulou; N Charlotte Onland-Moret; Eiliv Lund; Eric J Duell; Federico Canzian; Gianluca Severi; Kim Overvad; Marc J Gunter; Rosario Tumino; Ulrika Svenson; Andre van Rij; Annette F Baas; Matthew J Bown; Nilesh J Samani; Femke N G van t'Hof; Gerard Tromp; Gregory T Jones; Helena Kuivaniemi; James R Elmore; Mattias Johansson; James Mckay; Ghislaine Scelo; Robert Carreras-Torres; Valerie Gaborieau; Paul Brennan; Paige M Bracci; Rachel E Neale; Sara H Olson; Steven Gallinger; Donghui Li; Gloria M Petersen; Harvey A Risch; Alison P Klein; Jiali Han; Christian C Abnet; Neal D Freedman; Philip R Taylor; John M Maris; Katja K Aben; Lambertus A Kiemeney; Sita H Vermeulen; John K Wiencke; Kyle M Walsh; Margaret Wrensch; Terri Rice; Clare Turnbull; Kevin Litchfield; Lavinia Paternoster; Marie Standl; Gonçalo R Abecasis; John Paul SanGiovanni; Yong Li; Vladan Mijatovic; Yadav Sapkota; Siew-Kee Low; Krina T Zondervan; Grant W Montgomery; Dale R Nyholt; David A van Heel; Karen Hunt; Dan E Arking; Foram N Ashar; Nona Sotoodehnia; Daniel Woo; Jonathan Rosand; Mary E Comeau; W Mark Brown; Edwin K Silverman; John E Hokanson; Michael H Cho; Jennie Hui; Manuel A Ferreira; Philip J Thompson; Alanna C Morrison; Janine F Felix; Nicholas L Smith; Angela M Christiano; Lynn Petukhova; Regina C Betz; Xing Fan; Xuejun Zhang; Caihong Zhu; Carl D Langefeld; Susan D Thompson; Feijie Wang; Xu Lin; David A Schwartz; Tasha Fingerlin; Jerome I Rotter; Mary Frances Cotch; Richard A Jensen; Matthias Munz; Henrik Dommisch; Arne S Schaefer; Fang Han; Hanna M Ollila; Ryan P Hillary; Omar Albagha; Stuart H Ralston; Chenjie Zeng; Wei Zheng; Xiao-Ou Shu; Andre Reis; Steffen Uebe; Ulrike Hüffmeier; Yoshiya Kawamura; Takeshi Otowa; Tsukasa Sasaki; Martin Lloyd Hibberd; Sonia Davila; Gang Xie; Katherine Siminovitch; Jin-Xin Bei; Yi-Xin Zeng; Asta Försti; Bowang Chen; Stefano Landi; Andre Franke; Annegret Fischer; David Ellinghaus; Carlos Flores; Imre Noth; Shwu-Fan Ma; Jia Nee Foo; Jianjun Liu; Jong-Won Kim; David G Cox; Olivier Delattre; Olivier Mirabeau; Christine F Skibola; Clara S Tang; Merce Garcia-Barcelo; Kai-Ping Chang; Wen-Hui Su; Yu-Sun Chang; Nicholas G Martin; Scott Gordon; Tracey D Wade; Chaeyoung Lee; Michiaki Kubo; Pei-Chieng Cha; Yusuke Nakamura; Daniel Levy; Masayuki Kimura; Shih-Jen Hwang; Steven Hunt; Tim Spector; Nicole Soranzo; Ani W Manichaikul; R Graham Barr; Bratati Kahali; Elizabeth Speliotes; Laura M Yerges-Armstrong; Ching-Yu Cheng; Jost B Jonas; Tien Yin Wong; Isabella Fogh; Kuang Lin; John F Powell; Kenneth Rice; Caroline L Relton; Richard M Martin; George Davey Smith
Journal:  JAMA Oncol       Date:  2017-05-01       Impact factor: 31.777

7.  Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

Authors:  William Tapper; Amy V Jones; Robert Kralovics; Ashot S Harutyunyan; Katerina Zoi; William Leung; Anna L Godfrey; Paola Guglielmelli; Alison Callaway; Daniel Ward; Paula Aranaz; Helen E White; Katherine Waghorn; Feng Lin; Andrew Chase; E Joanna Baxter; Cathy Maclean; Jyoti Nangalia; Edwin Chen; Paul Evans; Michael Short; Andrew Jack; Louise Wallis; David Oscier; Andrew S Duncombe; Anna Schuh; Adam J Mead; Michael Griffiths; Joanne Ewing; Rosemary E Gale; Susanne Schnittger; Torsten Haferlach; Frank Stegelmann; Konstanze Döhner; Harald Grallert; Konstantin Strauch; Toshiko Tanaka; Stefania Bandinelli; Andreas Giannopoulos; Lisa Pieri; Carmela Mannarelli; Heinz Gisslinger; Giovanni Barosi; Mario Cazzola; Andreas Reiter; Claire Harrison; Peter Campbell; Anthony R Green; Alessandro Vannucchi; Nicholas C P Cross
Journal:  Nat Commun       Date:  2015-04-07       Impact factor: 14.919

Review 8.  Telomere length and common disease: study design and analytical challenges.

Authors:  Jennifer H Barrett; Mark M Iles; Alison M Dunning; Karen A Pooley
Journal:  Hum Genet       Date:  2015-05-19       Impact factor: 4.132

9.  The effect on melanoma risk of genes previously associated with telomere length.

Authors:  Mark M Iles; D Timothy Bishop; John C Taylor; Nicholas K Hayward; Myriam Brossard; Anne E Cust; Alison M Dunning; Jeffrey E Lee; Eric K Moses; Lars A Akslen; Per A Andresen; Marie-Françoise Avril; Esther Azizi; Giovanna Bianchi Scarrà; Kevin M Brown; Tadeusz Dębniak; David E Elder; Eitan Friedman; Paola Ghiorzo; Elizabeth M Gillanders; Alisa M Goldstein; Nelleke A Gruis; Johan Hansson; Mark Harland; Per Helsing; Marko Hočevar; Veronica Höiom; Christian Ingvar; Peter A Kanetsky; Maria Teresa Landi; Julie Lang; G Mark Lathrop; Jan Lubiński; Rona M Mackie; Nicholas G Martin; Anders Molven; Grant W Montgomery; Srdjan Novaković; Håkan Olsson; Susana Puig; Joan Anton Puig-Butille; Graham L Radford-Smith; Juliette Randerson-Moor; Nienke van der Stoep; Remco van Doorn; David C Whiteman; Stuart MacGregor; Karen A Pooley; Sarah V Ward; Graham J Mann; Christopher I Amos; Paul D P Pharoah; Florence Demenais; Matthew H Law; Julia A Newton Bishop; Jennifer H Barrett
Journal:  J Natl Cancer Inst       Date:  2014-09-17       Impact factor: 11.816

10.  Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans.

Authors:  Massimo Mangino; Shih-Jen Hwang; Timothy D Spector; Steven C Hunt; Masayuki Kimura; Annette L Fitzpatrick; Lene Christiansen; Inge Petersen; Clara C Elbers; Tamara Harris; Wei Chen; Sathanur R Srinivasan; Jeremy D Kark; Athanase Benetos; Said El Shamieh; Sophie Visvikis-Siest; Kaare Christensen; Gerald S Berenson; Ana M Valdes; Ana Viñuela; Melissa Garcia; Donna K Arnett; Ulrich Broeckel; Michael A Province; James S Pankow; Candace Kammerer; Yongmei Liu; Michael Nalls; Sarah Tishkoff; Fridtjof Thomas; Elad Ziv; Bruce M Psaty; Joshua C Bis; Jerome I Rotter; Kent D Taylor; Erin Smith; Nicholas J Schork; Daniel Levy; Abraham Aviv
Journal:  Hum Mol Genet       Date:  2012-09-21       Impact factor: 6.150

View more
  9 in total

1.  Genetically determined telomere length and multiple myeloma risk and outcome.

Authors:  Federico Canzian; Daniele Campa; Matteo Giaccherini; Angelica Macauda; Enrico Orciuolo; Marcin Rymko; Karolina Gruenpeter; Charles Dumontet; Malgorzata Raźny; Victor Moreno; Gabriele Buda; Katia Beider; Judit Varkonyi; Hervé Avet-Loiseau; Joaquín Martinez-Lopez; Herlander Marques; Marzena Watek; Maria Eugenia Sarasquete; Vibeke Andersen; Lionel Karlin; Anna Suska; Marcin Kruszewski; Niels Abildgaard; Marek Dudziński; Aleksandra Butrym; Arnold Nagler; Annette Juul Vangsted; Katalin Kadar; Tomczak Waldemar; Krzysztof Jamroziak; Svend Erik Hove Jacobsen; Lene Hyldahl Ebbesen; Michał Taszner; Grzegorz Mazur; Fabienne Lesueur; Matteo Pelosini; Ramon Garcia-Sanz; Artur Jurczyszyn; Delphine Demangel; Rui Manuel Reis; Elżbieta Iskierka-Jażdżewska; Miroslaw Markiewicz; Federica Gemignani; Edyta Subocz; Daria Zawirska; Agnieszka Druzd-Sitek; Anna Stępień; M Henar Alonso; Juan Sainz
Journal:  Blood Cancer J       Date:  2021-04-14       Impact factor: 11.037

Review 2.  The Genetic Makeup of Myeloproliferative Neoplasms: Role of Germline Variants in Defining Disease Risk, Phenotypic Diversity and Outcome.

Authors:  Elena Masselli; Giulia Pozzi; Cecilia Carubbi; Marco Vitale
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

3.  Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential.

Authors:  Tetsushi Nakao; Alexander G Bick; Margaret A Taub; Seyedeh M Zekavat; Md M Uddin; Abhishek Niroula; Cara L Carty; John Lane; Michael C Honigberg; Joshua S Weinstock; Akhil Pampana; Christopher J Gibson; Gabriel K Griffin; Shoa L Clarke; Romit Bhattacharya; Themistocles L Assimes; Leslie S Emery; Adrienne M Stilp; Quenna Wong; Jai Broome; Cecelia A Laurie; Alyna T Khan; Albert V Smith; Thomas W Blackwell; Veryan Codd; Christopher P Nelson; Zachary T Yoneda; Juan M Peralta; Donald W Bowden; Marguerite R Irvin; Meher Boorgula; Wei Zhao; Lisa R Yanek; Kerri L Wiggins; James E Hixson; C Charles Gu; Gina M Peloso; Dan M Roden; Muagututi'a S Reupena; Chii-Min Hwu; Dawn L DeMeo; Kari E North; Shannon Kelly; Solomon K Musani; Joshua C Bis; Donald M Lloyd-Jones; Jill M Johnsen; Michael Preuss; Russell P Tracy; Patricia A Peyser; Dandi Qiao; Pinkal Desai; Joanne E Curran; Barry I Freedman; Hemant K Tiwari; Sameer Chavan; Jennifer A Smith; Nicholas L Smith; Tanika N Kelly; Bertha Hidalgo; L Adrienne Cupples; Daniel E Weeks; Nicola L Hawley; Ryan L Minster; Ranjan Deka; Take T Naseri; Lisa de Las Fuentes; Laura M Raffield; Alanna C Morrison; Paul S Vries; Christie M Ballantyne; Eimear E Kenny; Stephen S Rich; Eric A Whitsel; Michael H Cho; M Benjamin Shoemaker; Betty S Pace; John Blangero; Nicholette D Palmer; Braxton D Mitchell; Alan R Shuldiner; Kathleen C Barnes; Susan Redline; Sharon L R Kardia; Gonçalo R Abecasis; Lewis C Becker; Susan R Heckbert; Jiang He; Wendy Post; Donna K Arnett; Ramachandran S Vasan; Dawood Darbar; Scott T Weiss; Stephen T McGarvey; Mariza de Andrade; Yii-Der Ida Chen; Robert C Kaplan; Deborah A Meyers; Brian S Custer; Adolfo Correa; Bruce M Psaty; Myriam Fornage; JoAnn E Manson; Eric Boerwinkle; Barbara A Konkle; Ruth J F Loos; Jerome I Rotter; Edwin K Silverman; Charles Kooperberg; John Danesh; Nilesh J Samani; Siddhartha Jaiswal; Peter Libby; Patrick T Ellinor; Nathan Pankratz; Benjamin L Ebert; Alexander P Reiner; Rasika A Mathias; Ron Do; Pradeep Natarajan
Journal:  Sci Adv       Date:  2022-04-06       Impact factor: 14.957

4.  Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis.

Authors:  Derek W Brown; Weiyin Zhou; Youjin Wang; Kristine Jones; Wen Luo; Casey Dagnall; Kedest Teshome; Alyssa Klein; Tongwu Zhang; Shu-Hong Lin; Olivia W Lee; Sairah Khan; Jacqueline B Vo; Amy Hutchinson; Jia Liu; Jiahui Wang; Bin Zhu; Belynda Hicks; Andrew St Martin; Stephen R Spellman; Tao Wang; H Joachim Deeg; Vikas Gupta; Stephanie J Lee; Neal D Freedman; Meredith Yeager; Stephen J Chanock; Sharon A Savage; Wael Saber; Shahinaz M Gadalla; Mitchell J Machiela
Journal:  Nat Commun       Date:  2022-09-08       Impact factor: 17.694

5.  Transcriptomic Analysis of Conserved Telomere Maintenance Component 1 (CTC1) and Its Association with Leukemia.

Authors:  Saadiya Zia; Netasha Khan; Komal Tehreem; Nazia Rehman; Rokayya Sami; Roua S Baty; Faris J Tayeb; Majed N Almashjary; Nouf H Alsubhi; Ghadeer I Alrefaei; Ramla Shahid
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

Review 6.  Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.

Authors:  Ruth Stuckey; María Teresa Gómez-Casares
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

7.  Germline POT1 variants can predispose to myeloid and lymphoid neoplasms.

Authors:  Tristan L Lim; David B Lieberman; Adam R Davis; Alison W Loren; Ryan Hausler; Ashkan Bigdeli; Yimei Li; Jacquelyn Powers; Anna Raper; Shannon A Carty; Katherine L Nathanson; Adam Bagg; Elizabeth O Hexner; Kara N Maxwell; Jennifer J D Morrissette; Daria V Babushok
Journal:  Leukemia       Date:  2021-06-30       Impact factor: 11.528

8.  Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition.

Authors:  Cristina Andrés-Zayas; Julia Suárez-González; Gabriela Rodríguez-Macías; Nieves Dorado; Santiago Osorio; Patricia Font; Diego Carbonell; María Chicano; Paula Muñiz; Mariana Bastos; Mi Kwon; José Luis Díez-Martín; Ismael Buño; Carolina Martínez-Laperche
Journal:  Mol Oncol       Date:  2021-07-16       Impact factor: 6.603

9.  Systematic review of Mendelian randomization studies on risk of cancer.

Authors:  Georgios Markozannes; Afroditi Kanellopoulou; Olympia Dimopoulou; Dimitrios Kosmidis; Xiaomeng Zhang; Lijuan Wang; Evropi Theodoratou; Dipender Gill; Stephen Burgess; Konstantinos K Tsilidis
Journal:  BMC Med       Date:  2022-02-02       Impact factor: 11.150

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.